2 secret growth stocks I’d buy and hold for 10 years

These two growth stocks should continue to produce results no matter what the future holds.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Companies that provide a critical business service for other firms often make the best investments as their revenues are sticky. In other words, itthey’res unlikely to disappear overnight as clients can’t switch to other offerings easily.

This is why I believe Alfa Financial Software (LSE: ALFA) and Microgen (LSE: MCGN) are perfect buy-and-forget growth stocks to hold for the next 10 years.

Profits double 

Today Alfa reported its first annual results since its IPO last year, showcasing its strengths. The company, which provides “mission critical software for the asset finance industry,” announced today that revenue for 2017 rose 20% to £88m, or 9% year-on-year to £86m at constant currency. Pre-tax profit surged to £34m, double last year’s reported figure of £17m.

However, it seems that the market is displeased with management’s growth outlook. Due to currency fluctuations, growth is expected to slow in 2018. Specifically, alongside today’s numbers, CEO Andrew Denton said a backdrop of a weakening dollar means the board expects to report low double-digit top line growth on a budget rate, or mid double-digit growth on a constant currency basis. It seems investors have also been disappointed by the lack of a dividend announcement for the year.

Still, despite this downbeat outlook, the long-term opportunity ahead of Alfa, and its peer Microgen, is tremendous. For example, Alfa estimates its addressable software market is over $3bn, compared to its current revenue run-rate of £88m ($123m).

City analysts are expecting the firm’s earnings per share to jump 15% for 2018 after last year’s surge in profitability. And as long as Alfa continues to provide a professional service to clients, I believe earnings can continue to grow at a double-digit rate for the foreseeable future.

Growth through acquisitions 

Bolt-on acquisitions are another tactic Alfa can use to boost growth. Microgen has chosen this route, using organic cash flow to buy up growth. In August of last year, the firm announced the acquisition of RevStream Inc, a California-based provider of revenue management enterprise software expanding its portfolio of mission-critical software businesses.

Following this deal, and others like it, the firm’s adjusted earnings per share increased by 39% to 17.1p for 2017, smashing City estimates of 15.2p. After this strong performance, it looks as if analysts are behind the curve with the company as they were expecting earnings per share of 18.3p for 2018. Considering 2017’s outperformance, I wouldn’t be surprised if analysts revised their forecasts for future growth substantially higher in the months ahead.

Unfortunately, the one problem with both Microgen and Alfa is that the shares currently command a high valuation. Shares in Microgen are trading at a forward P/E of 27.8 and Alfa is trading at a forward P/E of just under 40. While high, these valuations reflect the bespoke and sticky nature of these businesses’ revenue streams and future growth potential.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Rupert Hargreaves owns no share mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

8.6% or 7.2%? Does the Legal & General or Aviva dividend look better?

The Aviva dividend tempts our writer. But so does the payout from Legal & General. Here he explains why he'd…

Read more »

a couple embrace in front of their new home
Investing Articles

Are Persimmon shares a bargain hiding in plain sight?

Persimmon shares have struggled in 2024, so far. But today's trading update suggests sentiment in the housing market's already improving.

Read more »

Market Movers

Here’s why the Unilever share price is soaring after Q1 earnings

Stephen Wright isn’t surprised to see the Unilever share price rising as the company’s Q1 results show it’s executing on…

Read more »

Investing Articles

Barclays’ share price jumps 5% on Q1 news. Will it soon be too late to buy?

The Barclays share price has been having a great time this year, as a solid Q1 gives it another boost.…

Read more »

Young black colleagues high-fiving each other at work
Investing Articles

The AstraZeneca share price lifts 5% on a top-and-bottom earnings beat

The AstraZeneca share price reached £120 today and helped push the FTSE 100 higher. Would I still buy this flying…

Read more »

Young black woman using a mobile phone in a transport facility
Market Movers

Meta stock slumps 13% after poor results. Here’s what I’ll do

Jon Smith flags up the reasons behind the fall in the Meta stock price overnight, along with his take on…

Read more »

Young Caucasian girl showing and pointing up with fingers number three against yellow background
Investing Articles

3 FTSE stocks I wouldn’t ‘Sell in May’

If the strategy had any merit in the past, I see no compelling evidence it's a smart idea today. Here…

Read more »

Investor looking at stock graph on a tablet with their finger hovering over the Buy button
Investing Articles

Down 21% and yielding 10%, is this income stock a top contrarian buy now?

Despite its falling share price, this Fool reckons he's found an income stock that could be worth taking a closer…

Read more »